Full industry-pushing agenda

Become healthcare's solution


Be the solution: How Sanofi Pasteur is reengineering clinical trials together with health care systems

  • Understand how Sanofi is working with regulators and health care systems (including Kaiser Permanente) to build 1 million+ participant prospective trials
  • How machine learning is finding new correlations and understanding through large volumes of structured data
  • Understand why interoperability and data harmonization can unlock a new future for healthcare and the industry

David Loew EVP & Head Sanofi Pasteur


Fireside chat: Create a cure: why gene therapies have broken scientific boundaries and will now transcend commercial boundaries

  • How the 'science of gene therapy' has redefined what is possible for curative medicines
  • Join a candid discussion on how value models are being innovated to create access, fund innovation and meet stakeholder needs.

Jeff Marrazzo CEO Spark Therapeutics


Panel: Buckle up! Prepare for Election Year 2020 and ensure the odds are ever in your favor

  • Price control is a bipartisan issue; how will policy change as we head towards the 2020 election? Looking past the rhetoric to understand real policy and trends
  • Determine your pricing strategy in response – do you need to be aiming for the highest prices?
  • Best practice in planning with uncertainty: set strategy, ensure flexibility, find agility, go beyond 2020

Scott Howell VP and Head, US Market Access, Pharmaceuticals Novartis


How leadership can achieve competitive advantage through culture, values and vision

  • Understand how Takeda is making its values-based and patient-centered culture more robust to meet higher expectations
  • Find out how Takeda uses its principles to guide its decisions and enables the company to genuinely put patients before profits
  • Learn how nurturing curious, connected and courageous people creates a deep understanding of patients and innovative ways to support them

Ramona Sequeira President Takeda U.S.A


The soft stuff is hard: Why post-M&A success is defined by driving cultural change

  • Best practices for the integration journey: address common pitfalls and drive effective value capture.
  • Learn how to sensitize leadership to the employee experience in order to make non-spreadsheet decisions, faster.
  • Gain insights into the art and science of driving talent selection, employee engagement and retention strategies to capture the value of the deal.

Rob Scott Chief Medical Officer Abbvie


Our innovation model doesn’t respond to patient need: This is how we overhaul it

  • Why the architecture for R&D and commercial has created perverse incentives to ignore disease states – and how to introduce an innovation model that delivers for prevalent, chronic disease
  • Why advances in data science, open innovation and technology can deliver a patient-centric R&D model
  • Lessons learned from three years of harnessing wearables and always-on methods of capturing data in clinical trials


PANEL: How collaboration has unlocked the innovation we required for value-based care

  • The importance of collaboration as the primary way Industry can evolve and meet stakeholder demands to deliver more for less
  • The principles companies must improve upon to maximize stakeholder value
  • Spotlight on TransCelerate member work that has broken boundaries

Dalvir Gill CEO Transcelerate

The new frontier of customer engagement


Panel: Win the customer engagement race: Invest for success in 2020

  • What don’t customers want? Understand expectations and the value you can bring
  • Effective techniques for engaging tomorrow’s decision makers and strengthening brand loyalty of patients and HCPs
  • Where to invest resources to strike a successful balance between field and digital marketing channels
  • Incorporate the best and most relevant digital innovations into your customer engagement strategy

Sandra Yang US Omnichannel Strategy Director AstraZeneca

Paulo Amaral Global Zoster Multi Channel Marketing Lead GlaxoSmithKline

Ronnie Choudhary Senior Director, Global Customer Strategy Pfizer


Alkermes and Sunovion cast studies: Building a blueprint for IDN engagement at scale

  • How Sunovion defined the blueprint for IDN engagement by aligning team capabilities with commercial structure
  • Don’t get trapped in a bubble: how Alkermes created autonomy while staying connected to commercial function strategy
  • Attract, retain and invest in internal talent to build long-lasting, trusted customer partnerships

Matt Portch SVP, Sales and Market Access Sunovion Pharmaceuticals

Greg Apostol VP, Key Account Management & Field Reimbursement Alkermes


Combining advanced AI with the digitization of biology to empower patients and personalize healthcare

  • Discover how iCarbonX is using advanced AI to search big sets of biological data for new signals about health, disease and aging
  • Hear how it is transforming the health of individuals by unlocking the power of a deep and dynamic digitization of biology
  • Learn how the company’s platform can better classify conditions, refine diagnoses, and target treatments for specific biologies

Ted Tarasow, PhD Global Head Digital Biology R&D iCarbonX


Keep up with your customers: Match your digital engagement tactics to IDN maturity

  • Fewer customers, greater challenges: Assess the need for a digital engagement strategy tailored to IDNs
  • Overcome the challenges of scaling IDN strategy across customer groups with vastly differing digital sophistication
  • Understand what works: where do IDNs want support and how can data-driven digital help?

Make the most of data


Panel: Unleash the potential of data-driven compliance

  • Take the fear out of regulatory challenges and data privacy to make the most of your data and expand internal capabilities
  • Integrate and cross-reference data across your company and gain a 360 degree customer view
  • Identify and focus on the metrics that matter that provide true value to your business
  • Demonstrate improved outcomes for patients to gain their long-term loyalty and boost your bottom line

Melissa Fellner Global Consumer Marketing Director, Respiratory Biologics AstraZeneca

Russell Senyk US Marketing Director Luye

Zheng Yang Head of Technology and Data Innovation, Customer Value Boehringer Ingelheim


Knowing me, knowing you: Hyper-personalization as an achievable route to success

  • Harness your data insights to get up close and personal with your customers
  • Build trust and differentiate your brand by taking personal communications to a higher level, boosting familiarity, authenticity and authority
  • Consent as priority: demonstrate your respect for data confidentiality as a trust driver

Paul Bould VP, Global Marketing Insights Abbott


All in this together: Holding and sharing internal customer data

  • See what effective data ownership and management looks like when tailoring an effective strategy for your company
  • Integrate data ownership with analytics strategy and execute across functions to deliver intelligent engagements
  • Gain practical solutions to communicate collaboratively and break down internal barriers

Renaud Sermondade VP, Global Head of Insights & Analytics Sanofi

Collaboration is key


Collaboration unlocks the innovation we need for value-based care

  • Collaboration is the only way Industry can evolve and meet stakeholder demands to deliver more and charge with less
  • Understand how to work together to stakeholder value
  • Spotlight on one critical digital innovation breakthrough, which is coming through as a result of TransCelerate member work


Panel: Harness the combined power of commercial as sales, marketing & data evolve

  • Break down commercial silos as sales, marketing and data evolve to construct a unified view of the customer
  • Utilize cross-functional capabilities to build a sophisticated and authentic comprehension of patient value
  • Examine the shifting role of commercial ops as a support versus partnership function to the wider business, how leaders are achieving this and why it is important
  • Explore the common pitfalls related to data and insight exchange at the sales rep and field force level; and how leaders are overcoming these to provide optimal insights to their customers

Mundo Vega Associate Director - Global Commercial Operations, Business Analytics AbbVie

Christian Scheuer VP Global Commercial Affairs & Excellence LEO Pharma

Rj Lasek Vice President, Commercial Operations Takeda

Deliver on promises: Create visible value for patients and customers


All talk and no action? How tokenism is destroying patient trust

  • How ‘patient centricity’ is not a destination or even a goal- it’s a day-by-day process
  • How to hold yourself and your teams accountable through tangible metrics and prove you are really ‘patient-centric’

Laurie Meyers Head of CMG Patient Engagement Genentech


Fireside chat: How patient group can be the bridge to pre-competitive collaboration with RWE

  • IBD PLEXUS Case Study: How Crohn’s & Colitis Foundation united patients and pharma
  • Turn competitors into collaborators: how to build emergent coalitions

Caren Heller CSO Crohns Colitis foundation

Thomas Abbott Head, Real World Evidence Astellas


Panel: We need to talk about… health literacy

  • Make it easier for patients to deal with the wave of misinformation in the era of ‘post-truth’
  • Understand the best practices for communicating HCP and Regulatory data to patients
  • How we can work with patient advocacy groups, education forums and HCPs to communicate directly to patients and build higher levels of literacy and understanding

Laurie Myers Global Health Literacy Director Merck

Lori Hall Director, Global Health Literacy Eli Lilly

Esther Schorr Co-founder and COO Patient Power

John Linnell COPD Patient advocate


Build cross-functional understanding to navigate the diversity of patient entities

  • Why the explosion of patient entities – from expert patients trained in R&D, to advocacy leaders providing HTA input, to individuals living with disease – means it’s time to re-think our policies.
  • How to ensure appropriate company interactions across different patient entities

Amy Nicole Nayar Head, Global Patient relations Abbvie

Durhane Wong-Rieger President Canadian Organization for Rare Disorders


Where is tech innovation bringing real value in healthcare – and how are pharma companies keeping pace?

  • In which areas are new tech advances driving innovation in healthcare? How do pharma companies need to adapt to stay relevant?
  • Discover how strong data analysis is now seen as a core competency and where it can reveal unseen insights to add significant business value
  • Learn how integrating AI, blockchain, VR/AR and other emerging technologies is accelerating productivity and efficiencies across the industry
  • Understand how working with startups can accelerate digital innovation and foster new ways of working for better overall outcomes

Greg Silvesti Head of Digital Health & Innovation AbbVie

Douglas Arnold Director, Global Science, Technology and Commercialization, MMD IT Merck


Disrupting the healthcare model: The shift to patient control of drug access and treatment

  • Hear how GoodRx has changed access to medicines for over 20 million consumers via a free-to-use website and mobile app that tracks prescription drug prices and offers drug coupons across the US
  • Discover why this has led the company to launch GoodRx Care to provide online medical service to provide consultation, treatment, prescriptions and lab tests from doctors
  • Learn how the service is built to improve access, adherence, and affordability of medical care for all Americans and put control of healthcare firmly in the hands of patients

Emily McCarthy Senior Partnership Manager, Pharmacy Strategy GoodRx


Patient centricity in action. Take insights from concept to scale

  • Aligning on the use case and hypothesis
  • Starting small with pathways to scale
  • Determine what your key project outcomes could look like, based on AstraZeneca lessons learned

Dave Guiga Head of Portfolio Acceleration AstraZeneca

Build a data infrastructure that works


Sanofi case study: How Sanofi’s PISO team is breaking down silos to form new insights and solutions

  • How building a cross-departmental data integration structure revolutionized the capture, storage and usage of patient insights
  • Why building a scalable data-integrated structure across all relevant departments is vital for future-proofing your patient strategies

Joseph Collins Head, Medical Intelligence and Patient Perspectives Sanofi

Beth Brooks Patient Network Manager Sanofi


Fireside chat: How to reach a true holistic patient view

  • See why fusing data sources is the future of individualized patient interaction
  • How combining data insights with behavioral science can help segment patient populations to determine treatment pathways
  • How building holistic data patient portfolios breaks down access barriers to personalized care

Eric Racine VP and Head, North America Public Affairs & Patient Advocacy Sanofi

Marc Boutin CEO NHC


UCB Case study: How UCB achieved a practical pathway to their 2025 launch goals with a new process for strategic envisioning

  • Gain clarity and focus in your innovation teams by identifying concrete goals
  • Discover how UCB developed 4 visions of healthcare, that can be applied to any disease, resulting in an actionable launch strategy
  • See how UCB’s approach can identify each daily action you need to take to ensure that your pipeline is targeting future opportunities for differentiation building the capabilities to deliver on these expectations

Doug Stover VP, Global Head of Patient Experience and Technology Practice UCB


Fireside chat: Draft your fantasy pharma team: pair the right model and right vendors for your objectives

  • With increased sophistication of digital strategy, pharma can be helped and hindered by vendors. Should you build internal capabilities, or outsource?
  • Identify what is core to modern marketing and brand teams and how to futureproof your plans
  • Decide on the right operational approach for your company to take and get the most out of your investment in vendors
  • Best practices for change management and collaboration between internal and external teams – deliver more with less!

Wendy Kouba VP, Corporate Communications and Brand, Global Operations Teva

Overcome barriers to implementation


Panel: Create first-rate patient partnerships: Identify the metrics, improve internal structures and quantify success

  • How to identify concrete goals for patient engagement in regulatory, Product development, launch, access and commercial
  • Understand how to improve relationships with patient advocacy groups, holding both parties accountable to goals and metrics
  • How best to create an internal system that allows for easy scaling of patient initiatives and insights

Kristin Olson Senior Director, Patient Advocacy Seattle Genetics

Melissa Falcone VP, Patient Services and Reimbursement, Autoimmune and Rare Diseases Mallinckrodt

Jodie Gillon VP, Patient Advocacy & Clinical Affairs Abeona Therapeutics

Brett Kopelan Executive Director Debra

Terri Klien President and CEO MPS Society


FDA session focus 2020

  • Essential updates on the FDA learnings across its patient engagements
  • Understand key principles for engaging and coaching patients to engage
  • Case Study: How the FDA’s patient engagement framework created patient impact

Samir Shaikh Deputy Director for the Patient Affairs Staff FDA

Get on track to Pharma's digital future


Reinvent customer engagement from the outside-in

  • Discover how pioneering customer engagement models have propelled other industries to new levels of success – and which apply to you
  • Take from tech giants – identify web 2.0 models that can upgrade your communications without risking non-compliance
  • A guide to skills and processes that will be essential for tomorrow’s pharma leaders

Haider Alleg Global Head of Digital Excellence Ferring


Fireside chat: The ‘analytical rep of the future’:

  • As the face of pharma, the modern salesforce must embody digitally-enhanced customer value; learn how Novartis are leading the charge in their commercial functions
  • Develop a new commercial operational model which enables field units to connect to increasingly collaborative access, marketing, medical and patient functions
  • Patient value is the currency of tomorrow’s industry: Train your salesforce to deliver a seamless hybrid between face-to-face interaction and backend process

Bharti Rai VP Commercial Acceleration/ Effectiveness Novartis


How blockchain is reinventing the pharmaceutical supply chain

  • Hear the latest on the MediLedger initiative, a consortium approach to establish the use of blockchain in the healthcare industry
  • Find out why blockchain technologies having the potential to hugely increase transparency and improve risk management across the supply chain
  • Discover where else blockchain is starting to make a real impact on pharma company workflows and healthcare more broadly

Grant Harris Senior Director MediLedger


How VR is bringing a new reality to healthcare provision on the front line

  • Get insight on how Penn Radiation Oncology is using virtual reality in three core ways to improve their cancer treatment center experience for patients, families and staff
  • Discover where the technology helps specifically to reduce patient anxiety and give them and their caregivers a better understanding of information and treatment plans
  • Hear where the organization thinks virtual reality will have a critical ongoing role to play to support the management of conditions
  • Find out if they see a role for augmented reality in healthcare treatment too – and if so, where it could have the biggest impacts

Fern Nibauer-Cohen Director, Patient Engagement and Business Development Penn Radiation Oncology


Your external stakeholders have changed: has your strategy kept pace?

  • Medical’s stakeholders now include social media influencers, patient groups and digitally driven HCPs
  • Publishers have not kept up with changes in how your audience wants to consume Medical Information
  • Case Study: How we can collaborate cross-industry to create a new trusted digital resource for HCPs

Patrick Reilly CEO PhactMI


Panel: Your leadership model for customer centricity in the digital era

  • Define the role of digitally-driven sales teams, form the leadership team and set your commercial digital transformation strategy
  • Cultivate a data delivery system which empowers the ‘analytical sales rep of the future’ with well timed, well placed customer insights (medical, access, patient engagement)
  • Avoid and overcome common leadership pitfalls in the pursuit for digital domination

Soma Gupta Vice President, Global Marketing for Rare Disease Pfizer

Igor Rudychev Head, US Data & Innovations, Oncology Business Unit AstraZeneca

Hire, train and lead the pharma of the tomorrow


Panel: Invest time, money and manpower today to grow the commercial field force of the future

  • Smart commercial teams are those who are prepared, even ahead of change: Define the “top performer” of tomorrow and benchmark your commercial functions ahead of the curve
  • Hear about the existing commercial models that have proven to deliver an analytical and customer-first approach
  • Understand the process behind L&D programs and the requirements for creating the agile account managers at the forefront of pharma’s future

Jenn Muszik Head, US Commercial Learning Biogen

Frank Armenante Director, Sales Execution Novo Nordisk

Matt Portch SVP, Sales and Market Access Sunovion Pharmaceuticals

Tiffany McMacken Senior Director, Sales Training and Development Avanir Pharmaceuticals

Build A Sustainable Value Model


We must align to create a value model that supports breakthrough innovation

  • Presentation of key updates from ICER and the 2020 Value Assessment Framework
  • How do we value and reimburse high-cost therapies that can transform patient lives?
  • Where can payers and pharma work together to address affordability and create patient access

Chris Leibman SVP, Value and Access Biogen

Robert W. Dubois CSO & EVP National Pharmaceutical Council

Sarah Emond EVP and COO ICER

Karen Atkin Global Head of BioPharmaceuticals Medical AstraZeneca

Moderator: Andrew Kress CEO and Co-founder HealthVerity


IDN Panel: Where we want to work to co-create value

  • How Fairview is creating a forum for value-based partnership at the Pharma Symposium
  • What works and what doesn’t in pharma-provider co-creation
  • Provider Priorities: the biggest pain points where partnership could add value

Timothy Paine VP, Pharma Strategy & Relations Fairview Specialty Pharmacy

Jacob Jolly Director, Specialty Pharmacy Strategy and Market Access Vanderbilt University Medical Center

Melissa Skelton Senior Director, Ambulatory Pharmacy Services Banner Health

Access For Breakthrough Innovation


How is Spark breaking barriers to ensure patient access to Curative Care?

  • These are the critical barriers to Patient Access facing gene and cell therapy manufacturer today
  • How Spark created a new model to create access within our healthcare system to achieve 92% commercial coverage
  • Common sense changes that provide systemic change needed to accommodate affordability

Jay Newman Head of US Marketing and Patient Access Spark Therapeutics, Inc.


Financing the future: Precision financing innovations to enable patient access to durable, curative therapies

  • Understand innovative reimbursement models that address the financial challenges of these new therapies
  • Hear the implementation hurdles encountered by initial pilots
  • Learn how to tailor these approaches to product archetypes and payer segments

Mark Trusheim Strategic Director MIT NEWDIGS


Access and affordability is now a cross-functional priority

  • As the industry shifts towards value, access is everybody’s business
  • Hear Commercial, Patients and Medical leadership break down why the future of your function is driven by Access
  • As we converge around access and affordability, this is how we work cross-functionally to achieve our goals

AI Explorations


Take outcomes research into the future with AI

  • AI will transform our capabilities to generate and analyze RWE
  • Apply NLP to transform unstructured data, and incomplete EHRs, into usable evidence
  • Scale up your payer engagement and Market Access strategies with AI-assisted analysis

Anne Heatherington SVP, Head of Data Sciences Institute Takeda


Help IDNs identify patients who need treatment with AI

  • How to use AI to help IDNs identify patients living with an unmet need
  • Engage IDNs with RWE to prove unmet patient need
  • Pilot case study: How to utilize AI to connect patients to care

Sonal Bhatia, MD VP, North America Medical Lead, Rare Disease Pfizer


How and why AstraZeneca enlisted artificial intelligence for sales rep coaching

  • Learn how AstraZeneca’s AI strategy was developed to deliver value to their customers
  • Explore the capabilities of an AI-driven workforce by commercial application, tried and tested
  • Understand AstraZeneca’s need for enhanced training, coaching and progress monitoring and the process behind adopting AI to meet this
  • Hear how commercial leaders at AstraZeneca are measuring workforce effectiveness and productivity via AI

Spencer Holt PhD Head, Commercial Learning Innovation Centre AstraZeneca

Kevin Murray Associate Director, Commercial Leadership Excellence AstraZeneca

Evidence Creates Access


Unlock the potential of RWE for a cross-functional access strategy

  • RWE Primer: evolving definitions and uses of RWE
  • Create understanding internally of how RWE advances functional priorities
  • Apply RWE to complement and enhances cross-functional strategy for market access

Eric Wittbrodt Renal Evidence Strategy Lead AstraZeneca


Don’t confuse your customer, explain the value: how to integrate RWE in commercial engagement

  • Advance your go-to-market-strategy through RWE
  • Demystify and differentiate RWE from clinical evidence when you engage HCPs and payers
  • Create compelling value-stories with stakeholders to improve Access


Rebranding RWE: How to change how we talk about RWE and who accepts it

  • Learn which customers are ready to accept RWE now—and why
  • Understand why customers are skeptical and how to address their concerns
  • Diagnose gaps in your approach to demonstrating value with RWE

Madhavi Kasinadhuni Managing Director, Life Sciences Research Advisory Board

Health start-up challenge


Let the health entrepreneurs show you how

See what the most innovative health start-ups are doing to create value for patients and healthcare – then be the judge to crown the winner!

The following companies will deliver an elevator pitch during the plenary sessions, with the winner crowned on Day 3 Keynote Stage

  • NarrativeDx
  • Annexus Health
  • MirrorMe3D
  • Portable Medical Technology
  • Admetsys

Glenn Robertelli

Jordan Mills CEO MirrorMe3D

Kevin Bambury Co-Founder/Chief Commercial Officer Portable Medical Technology

Dr. Senem Guney Founder and Chief Patient Experience Officer NarrativeDx

Digital Clinical Trials


A moonshot trial with payers, providers and regulators

  • Pharma companies often cite the requirements of payers, providers and regulators as the reason for rigidity in trial design. Does that excuse still wash?
  • Examine what a co-created public-private partnership could generate in terms of trial design
  • Examine what’s required to build out a trial infrastructure/regulatory framework in a region that would enable digital trials to be done at scale

Jacob LaPorte Co-founder, BIOME Novartis


PANEL: The new clinical ecosystem – who will be disrupted, who will be displaced?

  • Gain market maturity by comprehending today’s spectrum of different approaches – from centralized PIs to virtual and remote networks. An objective perspective on the landscape of approaches and where they’re headed
  • Why new marketplaces and automation could disrupt CROs whilst new data, could disrupt pharma development organizations
  • How technology can disrupt the fundamental nature of trial participation for patients and likely pathways to progression

Craig Lipset Former Head of Clinical Innovation Formerly Pfizer


Fill the gaps: a universal system for patient referrals across partners

  • A new way to meet the criteria for existing clinical investigations which are not yet fulfilled
  • An evaluation of different approaches to minimize/replace control arms in prospective clinical trials – examine how models are progressing and what will it mean for future trials.
  • Determine whether there are pathways toward synthetic active arms in studies

Craig Lipset Former Head of Clinical Innovation Formerly Pfizer


What do the 5 million think? A new community for those who have participated in clinical research

  • How a more robust measurement of patient experience and peer-to-peer framing could change the perception paradigm of patients regarding clinical trials
  • Why a clinical research peer support community that's specific from disease communities (but works collaboratively with them) is a must-have
  • Details of the #FindtheFive campaign and how you can benefit

Irfan Khan CEO Circuit Clinical


PANEL: Patient-centric trials must be digital trials - and vice versa

  • Use technology to create patient-preferred trials – the trials patients would choose if they could. Integrate new processes to modernize the delivery of development
  • Raise ambitions with more personalized endpoints, align goals with patient advocates and deliver an improved Standard of Care
  • How to devise a shared mission to solve unmet need from the outset, with the FDA and EMA

David Lowe

Dalvir Gill CEO Transcelerate

Paul Simms Chairman eyeforpharma


Realize the promise of AI, RWE & Digital Health deployments through understanding of patient needs

  • Learn how to realize the promising potential of AI, RWE & Digital Health to transform patient care and clinical development.
  • A model to effectively develop and deploy innovative solutions that provides a path toward understanding and meeting patient needs.
  • Examples to include disease-specific NLP/ML algorithms to target patients eligible for clinical studies, AI-fused biosensors and monitoring to find deeper understanding on patients, and AI BOT assistants to support patients in disease management.

Juliette Chen Director, Global Outcomes Research and Epidemiology Takeda


Deliver health outcomes to minority populations who need it most

  • Why trust comes before technology: learn to use influencer networks to pull in disaffected populations that can demonstrate the greatest improvements in outcomes
  • Give clinics and doctors the resources and know-how to augment their capabilities and leverage their connections – using AI and automation to scale their influence
  • Have faith – take the long view and build relations with regulators and other gatekeepers as you embrace new technologies and processes.

Jason LaRoche Clinical Innovation Leader Janssen


Novel tial designs for research democratization

  • Trial design alternatives as the key to alternative options for patients
  • New types of trial design that enable democratization and a step change in ability to recruit and retain a targeted patient population
  • Perform heavy lifting through skilled change management

Kendal Whitlock Metasite Strategic Engagement Lead Boehringer Ingelheim


Out of the shadows: bring clinical to the people and create meaningful societal value

  • An update on efforts to build a federated data network linking EHRs across the country into a system-agnostic common data model
  • From the clinic and into the streets: removing the barriers, burdens and hurdles to greater clinical participation through frictionless technology
  • Use robust data science to build predictive models as we focus on value-based care

Jamie Roberts Director, Clinical Research Networks & Recruitment Innovation, CTSI Duke University


Working from scratch: how Pfizer is using digital wearables to reduce nightly itching and sleep deficit in atopic dermatitis

  • From idea to deployment: how Pfizer’s approach quantitively vetted and validated wearables to measure scratch and sleep, redesigning both studies and internally-built algorithms
  • The right team: how Universities of Rochester and Boston together with patient insights helped to co-create a series of new types of study in a sleep lab with thermal videography, or home environment
  • How to collaborate around analyzing the problem, designing studies, develop and testing methodology and understand the meaningfulness of the endpoint to the patient and outcome

Carrie Northcott Digital Medicine and Translational Imaging Pfizer


A higher standard: Sanofi’s Parkinsons initiative and how it will create a new standard of care

  • Combine rigorous standards with open communication to support the FDA, gain confidence in your endpoints and avoid being stuck on MVP/pilot
  • Natural-born collectors: how continuous-grade monitoring through smartphones and wearables can transform functional measures like balance, when supported with real kinematics research
  • How Sanofi’s all-encompassing digital strategy will support and benefit from superior clinical design

Laura Kling Digital Catalyst Sanofi


Continuous improvement: advocating a steady approach that enables holistic solutions for patients

  • Whilst moonshots can be exciting, the truth is that the future of our industry is not working in isolation, and parties must come together make change happen
  • Find ways to improve iteratively through smart use of agile development, scrums and MVPs with a careful approach to learning metrics
  • Learn to leapfrog: lessons in data and digital from the commercial centers of the organization that can be readily applied to clinical operations

Judy Sewards VP, Head of Clinical Trial Experience Pfizer


New endpoints, new beginnings: overcome perceived risks for new trial designs with unproven ROI

  • Learn how the ‘renegade’ Regeneron team is redefining new outcomes that work across clinical and RWE, with use of genetic sequencing
  • Feel the fear and do it anyway! Overcome perceived risks for new types of trial with unproven ROI
  • Rework organizational responsibilities to insource capabilities, break deadlocks, empower and support Clin Ops, and ensure trials are reimagined in a futureproof manner

Bari Kowal Vice President & Head, Global Clinical Operations Regeneron

Value, Driven


Medical Affairs can play a critical role in rebuilding customer trust and co-created value

  • Medical Affairs plays an important role in partnering with health systems as care shifts from volume to value
  • Medical Affairs needs to invest in strategic capabilities to co-create long-term value
  • Case study: How Pfizer is helping to build trusted provider partnerships to impact quality of care

Teresa Griesing VP, North America Medical Affairs Pfizer


Panel: The future of medical: Coordinators of value throughout lifecycle strategy

  • We are fundamentally changing: discover our new boundary between Commercial and R&D
  • Meet the surging resource demand from customers, without compromising scientific integrity
  • What organizational design and capabilities do we need to meet these expectations?

Rachele Berria, MD PhD VP, Head of Medical Affairs, US BioPharmaceuticals AstraZeneca

Paul Rowe, MD VP, Head of Global Medical, Immunology Sanofi Genzyme

Michael Norton VP, Head US Medical Affairs Abbvie

Harmony Garges Chief Medical Officer ViiV Healthcare


Step up to define your company-wide value strategy

  • Be the bridge for value between external and internal stakeholders
  • Set process to get stay focused on patient, payer and provider insights
  • Where we can work across the lifecycle to translate insights into value

Jefferson Tea VP, Medical & Scientific Affairs Takeda Canada


Patient group partnerships are the foundation of effective disease awareness strategy

  • Cultivate and nurture patient group outreach to build solid partnerships, based on trust
  • Case Study: How Novo Nordisk collaborated with Magic Foundation to map the patient journey
  • Use insights to support patients to self-advocate for better diagnosis and treatment

Nicky Kelepouris US Medical Director-Growth Hormone Novo Nordisk

Win back stakeholder trust


Systems thinking Is your key to improving quality outcomes for providers and patients

  • Medical must level-up healthcare system knowledge to keep up with stakeholder evolution
  • How patients flow within healthcare systems and the impact on clinical pathway
  • The future architecture of care: engage with complexity to improve quality outcomes

Eddie Power VP, North America Medical Affairs, Hospital Business Pfizer


Discover creative strategies to partner with IDNs with digital innovation driven by medical priorities

  • Turn to digital innovation to discover new ways to create value for IDNs
  • How Takeda collaborated with Advocate Health System to pilot clinical pathways for Mental Health
  • Turn validated ideas into a model that can work at scale


Adding the Medical Affairs Voice for Leveraging RWE and Big Data to Transform Tools for Payor Conversations

  • Collaborating with HEOR, Market Access, and Field Medical to determine payor needs, create a strategy, and execute
  • How Novo Nordisk is using RWE to help employers uncover employee health needs
  • Provide an example of how Medical Affairs can reestablish pharma’s credibility with customers by supporting access to industry’s big data

Gabriel Smolarz Medical Director Novo Nordisk


Take leadership on health literacy in Medical Affairs

  • We must elevate the importance of health literacy in medical comms while maintaining scientific integrity
  • The essential lessons medical can learn from R&D’s work to make health literacy common practice
  • The pathway to adoption: What can we learn from Europe in the USA?

Laurie Myers Global Health Literacy Director Merck


Panel: Put people before tech to create a digital culture that works for Medical

  • Shape the digital medical organization through cultural transformation
  • Upskill your team to create the capability to engage traditional audiences AND ‘Digital Opinion Leaders’
  • Stay relevant to how your audience consumes information while maintaining scientific integrity

Sebastian Sorsaburu VP Medical Affairs Amgen

Christopher Keenan Head, Worldwide Medical Customer Engagement, Medical Capabilities Bristol-Myers Squibb

Meg Heim VP, Global Head of Scientific Engagement Strategy, Operations and Program Management Sanofi


Start with customer experience to create effective digital strategy for medical engagement

  • Digital and beyond: how to ensure your scientific comms strategy reaches and engages your audience
  • Reducing customer effort is THE critical principle to test your digital strategy against
  • The best content and strategy will fail if you can’t engage on time: improve your speed without increasing risk

Christopher Keenan Head, Worldwide Medical Customer Engagement, Medical Capabilities Bristol-Myers Squibb


Your external stakeholders have changed: has your strategy kept pace?

  • Medical’s stakeholders now include social media influencers, patient groups and digitally driven HCPs
  • Publishers are in search of innovative digital ways for providers, payors, and patients to consume scientific/medical information
  • Case Study: How we can collaborate cross-industry to create a new trusted digital resource for HCPs

Roundtable Sessions


Customer engagement roundtable sessions

  • Improving patient messaging: Literacy, advocacy and marketing
  • Building and growing your long-term loyal customer base
  • Meet your patient – where patients are spending their time on social media (partnerships)
  • How to effectively communicate RWE within your customer engagement strategy (data science and application)
  • Improving customer engagement across the board with digitally-driven sales teams


Digital transformation roundtable sessions

  • Results in real time – make the most of digital ROI (data science and application)
  • The new sound of healthcare – how voice assistants can spark behavioural change (customer engagement)
  • Direct patient interaction: Solutions to the social media dilemma - PATIENT LED
  • Shape your digital strategy around realistic commercial capabilities and long-term sales goals


Visible value roundtable sessions

  • Creating visible value for patients - what and how?
  • Demonstrate visible value with a sophisticated commercial strategy around data/insight sharing
  • How payers and pharma can work together to address affordability and create patient access
  • Co-creating value: The patient, customer, pharma relationship


Access roundtable sessions

  • Advance value-based contracts by proving their worth to payers through RWE (visible value)
  • Deconstruct the DTX (digital therapeutics) revolution and access
  • Breaking down the biggest policy impacts on Access 2020 (visible value)
  • Partnering in advocacy for visible value creation


Data science and application roundtable sessions

  • Data strategy must change in order to enable VBC/value-based contracts
  • Patient access to data – understanding ownership, returns and security
  • How Artificial Intelligence is shaping the way commercial functions train, marketing and sell value to customers
  • Get the most from your sales teams by harnessing the power of advanced data analytics and insight communication


Innovation roundtable sessions

  • How to use quick iterative planning to meet long-term goals
  • How pharma and medical device companies can change the patient landscape
  • How face to face virtual support can help change the outcome for patients
  • How virtual and augmented reality are enabling more intuitive medical visualization, education and new treatment pathways


Partnerships roundtable sessions

  • Supporting caregivers as well as patients
  • Building trust between patients and pharma
  • Supporting caregivers as well as patients
  • Ahead of change: Discuss medical’s new boundary between commercial and R&D
  • Get the most out of blended vendor and in-house teams
  • Getting the most from patient collaboration in Clinical

Pre-conference workshops (April 14, Pharma Only)


Pre-conference workshop: Key account management (KAM) in pharma

Applying best practices in KAM for business results

As the Pharma industry continues to consolidate, we are starting to see beyond boarders. Companies are facing intense pressure to differentiate themselves from the competition and avoid commoditization of their offerings bringing added value and value based to the conversation. Commercial teams are responding by trying to sell value but are generally being rebuffed by disinterested buyers.

Our workshop will show a proven alternative approach to co-create value with and become strategic to your largest and most important customers. The Strategic Account Management Association will run a short introductory session to reach a common understanding on the principles of SAM where successful practitioners will share not only what they did, but how they did it in a highly interactive session.

Click here for more details on the workshop, key takeaways and core audience

(SAMA) Strategic Account Management Association - Logo

Moderated by the Strategic Account Management Association and leading pharma companies.


Pre-conference workshop: Designing the optimal organizational structure for business innovation

This workshop, hosted by the Digital Health Coalition, will convene thought leaders from various pharmaceutical companies and change management firms to explore how organizational structure, culture, and communication can impact the success of business innovation initiatives – or limit their long term adoption. Whether it means bringing innovation in-house, developing smart strategic partnerships, or adopting agile marketing, all marketers are now being asked to re-examine the structure of their teams. The content and discussion topics of this workshop are designed for HCP and patient marketers, brand leads, and digital COE roles.

Click here for more details on the workshop, key takeaways and core audience

(DHC) Digital Health Coalition - Logo

Moderated by the Digital Health Coalition and leading pharma companies.